Signant Health Acquires Ametris to Expand Digital Clinical Trial Solutions

Signant Health, a global leader in electronic Clinical Outcome Assessment (eCOA) and eClinical solutions backed by Harvest Partners and Genstar Capital, has acquired Ametris, a US-based digital health solutions provider, from ARCHIMED HEALTHCARE IT’s MED II fund. The acquisition integrates Ametris’ wearable-derived digital outcome measures with Signant’s patient-reported outcomes platform, creating a comprehensive, end-to-end clinical evidence solution for pharmaceutical sponsors worldwide. The deal was announced on May 28, 2026.

Founded in 2004 as ActiGraph, Ametris transformed under ARCHIMED’s ownership from a hardware-focused actigraphy specialist into a software-led leader in FDA-approved digital endpoints and decentralized clinical trials. The company supports over 260 industry-sponsored trials across more than 150 countries and serves the top 25 pharmaceutical companies globally.

ARCHIMED HEALTHCARE IT, part of the global private equity firm ARCHIMED, acquired ActiGraph in 2020 and rebranded it as Ametris. Through a strategic focus on internationalization, innovation, and M&A, ARCHIMED expanded Ametris’ footprint and capabilities. Key milestones include the launch of LEAP, a next-generation biometric sensor cleared by the FDA in October 2023, and the acquisition of Biofourmis Connect in October 2024, which made the platform device-agnostic and enhanced its algorithmic offerings.

Robin Filmer-Wilson, Partner at ARCHIMED, commented, “Ametris is a textbook example of ARCHIMED’s playbook: source a science-driven business at an inflection point and scale it into a global category leader. Signant Health is the natural next home — together they create the integrated, multimodal evidence platform sponsors have been asking for.” Jeremy Wyatt, CEO of Ametris, who will remain post-transaction, added, “ARCHIMED has been the right partner for this journey. Their international expansion expertise allowed us to globalize and transform Ametris into a truly international player.”

The acquisition addresses a growing $1.1 billion market characterized by a shift in clinical research from subjective measures to continuous, sensor-derived digital endpoints accepted by regulators. By combining Signant’s leadership in patient-reported outcomes with Ametris’ advanced wearable technology and regulatory-aligned analytics, the deal positions Signant Health as a purpose-built, end-to-end clinical evidence platform for the pharmaceutical industry.

Financial terms of the transaction were not disclosed. ARCHIMED’s MED II fund, which acquired Ametris in 2020, has invested in 11 companies through majority buyouts and has already returned 2x cash-to-cash to investors, with a total value to paid-in (TVPI) multiple of 2.7x. ARCHIMED is recognized as a top-tier healthcare-focused private equity firm managing $11 billion across its funds.

Looking ahead, Signant Health plans to integrate Ametris’ wearable sensor data with its patient-reported outcomes platform to enhance data analytics and trial execution efficiency. The combined platform aims to streamline regulatory compliance and scientific support while expanding global reach through Ametris’ presence in over 150 countries.

Industry experts note that this acquisition accelerates consolidation in the digital clinical trial solutions market, increasing competitive pressure on other providers to develop integrated, multimodal platforms. Challenges remain in aligning technology platforms, organizational cultures, and regulatory standards, as well as retaining key scientific talent during integration.

Overall, the deal strengthens Signant Health’s market position and expands its product offerings, meeting growing demand for decentralized clinical trials and continuous digital endpoints. The integration is expected to deliver enhanced value to pharmaceutical sponsors seeking comprehensive, validated clinical evidence solutions.